1 published article · Updated continuously
27 trials tracked for Lung diseases: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 429 citations.
Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Patient-controlled analgesia (PCA) was evaluated for pain management in lung disease patients, with results showing varied Visual Analogue Scale (VAS) scores and M.D. Anderson Symptom Inventory (MDASI) scores across study groups 1.
Roflumilast did not demonstrate a statistically significant difference in the rate of moderate or severe COPD exacerbations per patient per year (p=0.1634), nor in the rate of exacerbations leading to hospitalization or death (p=0.6354) 3.
Active CPAP was shown to have a statistically significant effect on certain neurocognitive functions, specifically improving E/F Function- SWMT-OMD (p=0.0074), while showing no significant impact on A/P Function (p=0.4538) or L/M Function (p=0.7936) 5.
Ceftolozane/tazobactam was evaluated for mortality and clinical response; the percentage of patients with all-cause mortality at Day 28 was 24.0% and 25.3%, while clinical cure rates were 54.4% and 53.3% 6.
Montelukast was studied in infants, where observed wheezing-free days were recorded as 25.5 and 30.5 7.
Placebo groups showed specific changes in the rate of asthma-free days (11.3; 9.3; 9.3) and height from baseline to end of treatment (22.7; 23.7; 23.8) over a period of 4-6 years 9.
Esomeprazole did not show statistically significant differences in episodes of poor asthma control (p=0.66), peak expiratory flow drops (p=0.35), or urgent care visits (p=0.79) 10.
AI synthesis of 9 cited trials, updated Jul 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
